CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

NCT00323323 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: CHOP
DRUG: Alemtuzumab
PROCEDURE: Plasma Samples

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]